You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬邦德(002082.SZ):終止重大資產重組事項

格隆匯11月1日丨萬邦德(002082.SZ)公佈,2022年11月1日,萬邦德醫藥控股集團股份有限公司召開第八屆董事會第二十次會議、第八屆監事會第十八次會議,審議通過了《關於終止重大資產重組事項的議案》,同意公司終止此次重大資產重組並簽署《<Consun Pharmaceutical Group Limited>之股份轉讓意向協議之終止協議》。

此前披露,公司擬通過支付現金方式收購康臣藥業集團有限公司(Consun Pharmaceutical GroupLimited)(股份代號:1681,簡稱“康臣藥業”、“目標公司”)合計238,056,948股普通股股份,佔目標公司已發行股份(“目標股份”)的29.50%,總代價是按照目標公司的整體股權預估值為人民幣約74億元,以2022年7月25日總股本計對應目標股份的預估轉讓價格為每股人民幣約9.17元。

自公司籌劃此次重大資產重組事項以來,公司嚴格按照相關法律法規要求,聘請了中介機構,積極組織工作團隊,配合中介機構推進盡職調查、審計、評估、法律核查等相關工作,全力推進此次重大資產重組事項,與此次重大資產重組有關各方進行了積極磋商、探討和溝通。截至公吿日,萬邦德與Central Success Developments Limited、Double Grace International Limited、黎倩及安猛最終未能就交易方案中的核心條款達成一致意見,經友好協商,各方同意終止《股份轉讓意向協議》。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account